A carregar...
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
BACKGROUND: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On...
Na minha lista:
| Publicado no: | Clin Transl Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5243239/ https://ncbi.nlm.nih.gov/pubmed/28101782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-016-0133-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|